Claims
- 1. A bis-biguanide compound having the generic formula: ##STR3## wherein n is from 2 to 4 inclusive; wherein X and X' each represent an alkylene radical containing from 1 to 3 carbon atoms; wherein z and z' are selected from the group consisting of 0 to 1; wherein R and R' are each selected from the group consisting of hydrogen, alkyl radicals containing from 1 to about 12 carbon atoms and aralkyl radicals containing from 7 to about 12 carbon atoms; and wherein R.sub.2 and R.sub.2 ' are each selected from the group consisting of hydrogen and alkyl radicals of 1 to 2 carbon atoms; and the pharmaceutically acceptable salts thereof.
- 2. The compound of claim 1 wherein said salt is a water-soluble salt.
- 3. The compound of claim 2 wherein the salt is selected from the group consisting of the dihydrochloride, diacetate and digluconate salts.
- 4. The compound of claim 1 wherein n equals 2, z and z' are each O and R, R', R.sub.2 and R.sub.2 ' are each hydrogen.
- 5. The compound of claim 4 wherein the trifluoromethyl groups are in the meta position.
- 6. The compound of claim 4 wherein said compound is a pharmaceutically acceptable, water-soluble salt.
- 7. The compound of claim 5 wherein said compound is a pharmaceutically acceptable, water-soluble salt.
- 8. The compound of claim 7 wherein said salt is selected from the group consisting of the dihydrochloride diacetate and digluconate salts.
- 9. An oral composition comprising a carrier suitable for use in the oral cavity and from about 0.01% to about 2.5% of an antiplaque agent having the formula: ##STR4## wherein n is from 2 to 4 inclusive; wherein X and X' each represent an alkylene radical containing from 1 to 3 carbon atoms; wherein z and z' each are selected from the group consisting of 0 to 1; wherein R and R' are selected from the group consisting of hydrogen, alkyl radicals containing from 1 to about 12 carbon atoms and aralkyl radicals containing from 7 to about 12 carbon atoms and wherein R.sub.2 and R.sub.2 ' each are selected from the group consisting of hydrogen and alkyl radicals of 1 to 2 carbon atoms, and the pharmaceutically acceptable salts thereof.
- 10. The composition of claim 9 wherein said antiplaque agent is in the form of a water-soluble, pharmaceutically acceptable salt.
- 11. The composition of claim 10, wherein said salt is selected from the group consisting of the dihydrochloride, diacetate and digluconate salts.
- 12. The composition of claim 9 wherein n equals 2, z and z' are each O and R, R', R.sub.2 and R.sub.2 ' are each hydrogen.
- 13. The composition of claim 12 wherein the trifluoromethyl groups in the antiplaque agent are in the meta position.
- 14. The composition of claim 12 wherein said antiplaque agent is a pharmaceutically acceptable water-soluble salt.
- 15. The composition of claim 13 wherein said antiplaque agent is in the form of a pharmaceutically acceptable water-soluble salt.
- 16. The composition of claim 15 wherein said salt is selected from the group consisting of the dihydrochloride, diacetate and digluconate salts.
- 17. The compositions of claim 16 wherein the amount of antiplaque agent in said composition is from about 0.05% to about 1.2%.
- 18. The composition of claim 16 in the form of a dentifrice wherein said antiplaque agent is present at a level of from about 0.1% to about 2.0% and wherein said composition contains as an additional ingredient from about 0.5% to about 95% of an abrasive.
- 19. The composition of claim 16 in the form of a mouthwash wherein said antiplaque agent is present at a level of from about 0.5% to about 1.5% and wherein said composition contains as additional components:
- A. from about 5% to about 40% ethyl alcohol;
- B. from 0% to about 20% humectant;
- C. from 0% to about 2% sudsing agent;
- D. from 0% to about 0.5% sweetening agent;
- E. from about 0.05% to about 0.3% flavoring agent; and
- F. the balance water.
- 20. A composition in accordance with claim 9 which additionally contains from about 0.01% to about 1.25% by weight of the composition of a chelator in excess of the amount of chelator which will react with the bis-biguanide compound, said chelator being selected from the group consisting of nitrilotriacetic acid, ethylenediamine diacetic acid, kojic acid, maltol, ethyl maltol, calcium dihydrogen ethylenediamine tetraacetate, di-N-substituted ethylene diamine diacetic acids wherein the substituents are selected from the group consisting of ethyl and 2-hydroxyethyl and the pharmaceutically acceptable water-soluble salts of said chelators.
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of the abandoned application of Prem S. Juneja having Ser. No. 601,244, filed Aug. 1, 1975.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4001393 |
L'Orange |
Jan 1977 |
|
Non-Patent Literature Citations (1)
Entry |
Warner et al., J. Med. Chem., vol. 16, pp. 732-733, (1973). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
601244 |
Aug 1975 |
|